DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 37+ companies and 40+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in EGFR Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ EGFR Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report

• June 2024:- Merck Sharp & Dohme LLC- A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors.
• June 2024:- AstraZeneca- Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
• June 2024:- Summit Therapeutics- A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment.
• June 2024:-Teligene US- A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I). This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
• June 2024:- Sichuan Baili Pharmaceutical Co., Ltd.- A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer After Failure of Anti-PD-1/PD-L1 Monoclonal Antibodies and Platinum-based Chemotherapy. This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy.
• DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report depicts a robust space with 37+ active players working to develop 40+ pipeline therapies for EGFR Non-Small Cell Lung Cancer treatment.
• The leading EGFR Non-Small Cell Lung Cancer Companies such as Cullinan Oncology, Taiho Pharmaceutical, ORIC Pharmaceuticals, Ono Pharmaceutical, Nuvalent, Shanghai Junshi Biosciences, Janux Therapeutics, HK inno.N, HUTCHMED, Daiichi Sankyo Company, and others.
• Promising EGFR Non-Small Cell Lung Cancer Therapies such as Vebreltinib, PLB1004, Gefitinib, Osimertinib, Amivantamab, Lazertinib, Zirabev, Sunvozertinib, BBT-207, SKB264, TRX-221, and others.

Stay informed about the cutting-edge advancements in EGFR Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ EGFR Non-Small Cell Lung Cancer Clinical Trials Assessment

EGFR Non-Small Cell Lung Cancer Emerging Drugs Profile

• Zipalertinib: Cullinan Oncology

Zipalertinib is a next-generation oral, irreversible, small molecule designed to target EGFR activating mutations, including EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR. The FDA granted breakthrough therapy designation to zipalertinib for the treatment of patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations and who have received prior platinum-based chemotherapy. The drug is currently being evaluated under Phase III clinical studies for the treatment of non-small cell lung cancer.

• BBT-176: Bridge Biotherapeutics

BBT-176 is a novel epidermal growth factor receptor – tyrosine kinase inhibitor (EGFR-TKI), which is designed to inhibit EGFR with C797S mutations, which arise as Tagrisso (osimertinib) resistant mutations following Tagrisso treatment in non-small cell lung cancer (NSCLC). In the pre-clinical studies, BBT-176 exhibited strong anti-tumor efficacy in C797S triple mutations. The drug is in the Phase I/II stage of development for the treatment of non-small-cell lung cancer.

• ORIC-114: ORIC Pharmaceuticals

ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, making it a promising therapeutic candidate to address the unmet medical need of having both meaningful systemic as well as CNS antitumor activity. It is currently being evaluated under Phase I clinical study for the treatment of non-small-cell lung cancer.

Learn more about EGFR Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking EGFR Non-Small Cell Lung Cancer Research and development projects @ EGFR Non-Small Cell Lung Cancer Unmet Needs

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in EGFR Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ EGFR Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

EGFR Non-Small Cell Lung Cancer Companies and Drugs

• Therapex Co.  Ltd:- TRX-221
• Avistone Biotechnology Co., Ltd.: PLB1004
• Merck Sharp & Dohme LLC: Pemetrexed
• Dizal Pharmaceuticals: DZD9008
• Betta Pharmaceuticals Co., Ltd.: Icotinib Hydrochloride Tablets

Scope of the EGFR Non-Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• EGFR Non-Small Cell Lung Cancer Companies-  Cullinan Oncology, Taiho Pharmaceutical, ORIC Pharmaceuticals, Ono Pharmaceutical, Nuvalent, Shanghai Junshi Biosciences, Janux Therapeutics, HK inno.N, HUTCHMED, Daiichi Sankyo Company, and others.
• EGFR Non-Small Cell Lung Cancer Therapies- Vebreltinib, PLB1004, Gefitinib, Osimertinib, Amivantamab, Lazertinib, Zirabev, Sunvozertinib, BBT-207, SKB264, TRX-221, and others.
• EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of EGFR Non-Small Cell Lung Cancer Pipeline on our website @ EGFR Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. EGFR Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Zipalertinib: Cullinan Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ORIC-114: ORIC Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. NVL-330: Nuvalent
18. Drug profiles in the detailed report…..
19. Inactive Products
20. EGFR Non-Small Cell Lung Cancer- Collaborations Assessment- Licensing / Partnering / Funding
21. EGFR Non-Small Cell Lung Cancer- Unmet Needs
22. EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/